Shift5 protects the operational technology (OT) that underpins our modern connected world from cyber attack. Today's planes, trains, and tanks, to name just a few examples, rely on complex internal data networks that are susceptible to cyber attack. Shift5 provides cyber security products to prevent, detect, and alert against hacks on these internal data bus networks. By mitigating the entire attack life cycle against an OT system, Shift5 provides a unified security solution that enables system operators, maintainers, managers, and incident responders. We go one step further - by providing enriched system data for operations analysts searching for cost savings, or revenue opportunities. Contact us today to discuss how we can secure your OT and provide insights to operate more efficiently.

Tech Services

0 - 50 employees

Washington D.c., United States

Redjack

Redjack tackles the most critical intelligence challenges for enterprises and the government. We fight for the truth to make the world safer for business, democracy, and humanity. Our original technology emerged from national intelligence agencies, where it is still widely deployed today. In 2007, we launched Redjack with the mission of making an even bigger impact by making the truth accessible to the larger world. We serve customers including the Fortune 100 and the largest government agencies. Our team of experts includes engineers, data scientists, business analysts, and research scientists. They join Redjack for the opportunity to work on complex, important challenges.

IT Security

0 - 50 employees

Washington D.c., United States

Arcellx

Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. The Company's proprietary ARC-sparX platform separates the tumor-recognition and tumor-killing functions of conventional CAR-T cell therapies: (1) sparX (soluble protein antigen-receptor X-linkers) proteins recognize and bind specific antigens on diseased cells and flag those cells for destruction; and (2) ARC-T (Antigen Receptor Complex-T) cells bind the sparX proteins and kill the flagged cells. Arcellx has developed a collection of sparX proteins that bind different cell surface antigens. Administration of alternate sparX proteins can redirect ARC-T cells to different disease antigens to potentially address relapsed and refractory disease due to tumor heterogeneity or antigen escape. Additionally, ARC-T cell activity can be curbed as needed by controlling the dose and frequency of sparX administration.

Biotech

50 - 250 employees

Washington D.c., United States

Browse All Companies

Latest Jobs in Washington D.C.

Washington D.C. based companies

Check out more Jobs in other cities

Your tracker settings